Cycle on Jul 20, 2026

I will begin by listing the open threads and watches for this topic using `list_threads` to identify the specific research goals or active monitoring tripwires set up in previous cycles.

I will pull the public-market views for the five key companies highlighted in the brief—Eli Lilly (LLY), Novo Nordisk (NVO), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR)—to ground our analysis in their latest financials, valuations, and stock performance.

I will now pull the public-market views for Novo Nordisk (NVO), Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR). I'll execute them sequentially. First, Novo Nordisk (NVO).

I will now pull the public-market views for Amgen (AMGN), Viking Therapeutics (VKTX), and Structure Therapeutics (GPCR). Let's do AMGN first.

I will now pull the public-market views for Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR). Let's do VKTX first.

I will now pull the public-market view for Structure Therapeutics (GPCR).

I see a few very interesting things in the market views: 1. **Novo Nordisk (NVO)** won European Commission approval for its **oral Wegovy pill** on July 16, 2026. This is a massive development (the first oral GLP-1 cleared for weight management in the EU). Let's search for details on this approval, including dosing, clinical results, and expected launch timeline. 2. **Viking Therapeutics (VKTX)** has initiated a Phase 1 study for **VK3019**, an amylin-based weight loss therapy, and has animal data showing strong weight-loss signals. Also, we need to check on their Q2 2026 earnings (set to report soon) and their VK2735 pipeline (the oral Phase 3 and the Q3 Phase 1 maintenance study). 3. **Structure Therapeutics (GPCR)** has been presenting at conferences (Jefferies, Morgan Stanley) discussing oral GLP-1 (aleniglipron / GSBR-1290) and Amylin therapies. 4. Let's look for other developments across the industry, including Eli Lilly's oral orforglipron (Foundayo) and Amgen's MariTide. Let's do a web search on Novo Nordisk's oral Wegovy EU approval to understand what exactly got approved, the clinical data behind it (OASIS-1 trial?), and the commercial plans. I'll also search for Viking's VK3019 and Amgen's MariTide. Let's start with Novo Nordisk's oral Wegovy pill approval in the EU.

This is a very significant event! Let's fetch the FiercePharma article `https://www.fiercepharma.com/pharma/novo-gets-head-start-lilly-europe-ec-approval-wegovy-pill-0` and the Pharmaceutical Technology article `https://www.pharmaceutical-technology.com/news/novo-secures-european-approval-for-oral-wegovy-to-extend-lead-over-lilly/` to get the details of the EU oral Wegovy approval. I'll start with FiercePharma.

This is incredibly rich data! Let's analyze what we have here: 1. **Novo Nordisk's oral Wegovy (25mg semaglutide pill)** won European Commission approval on July 15, 2026. It is the first and only oral GLP-1 receptor agonist approved for weight management in the EU. 2. In addition to the oral Wegovy pill, the European Commission also approved the **high-dose, 7.2-mg version of the Wegovy pen** (which the FDA approved in March 2026). 3. The clinical trial for the high-dose Wegovy pen was the **Step Up trial** (72 weeks), showing 20.7% weight loss for the 7.2-mg dose vs 17.5% for the 2.4-mg dose and 2.4% for placebo. 4. The trial for the oral Wegovy pill was the **Oasis trial** (daily 25-mg dose), which produced 17% weight loss compared with 3% for placebo. 5. In Q1 2026, Novo reported **$355 million in sales of the Wegovy pill** (meaning it's already launched in the US). 6. Compare this to Eli Lilly's oral GLP-1 **Foundayo (orforglipron)**, which is also on the market in the US. In the US, IQVIA data shows the Wegovy pill logged **153,000 weekly U.S. prescriptions**, compared with **19,550 for Foundayo** in its 13th week on the market. In its own 13th week, Wegovy pill had logged 105,000. This shows Novo has a strong early lead in the oral market in the US. 7. For the EU/UK launch of Foundayo, Eli Lilly's International President Patrik Jonsson mentioned that the launch could come by the end of 2026 or early 2027, and that Trump's "most favored nations" (MFN) pricing policy will play a role for all launches. Wait, let's look at our active watches! We have a watch: - `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` (ID: `019f1276-a5e0-7c66-acda-94e3069c4e57`): "Eli Lilly plans to launch its newly FDA-approved oral weight-loss drug Foundayo (orforglipron) in Europe and the UK in late 2026 or early 2027 following regulatory approvals..." This watch is set for `one_shot` with a fire date of March 31, 2027. It hasn't happened yet, but we have updated commentary (Lilly's Patrik Jonsson saying it could come by the end of the year or early 2027). Let's do a search on Viking Therapeutics' VK3019 and VK2735. Specifically, let's search for "VK3019" and "Viking Therapeutics" "Phase 1" or "amylin". Let's also look for updates on Viking's Q3 2026 VK2735 Phase 1 maintenance study readout or oral VK2735 Phase 3 trial initiation. And let's search for Structure Therapeutics (GPCR) and aleniglipron. Let's do a web search first.

Let's fetch the Viking Therapeutics press release from June 24, 2026: `https://ir.vikingtherapeutics.com/2026-06-24-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Study-to-Evaluate-Novel-Amylin-Receptor-Agonist-VK3019-in-Healthy-Adults` to understand VK3019 and see if there are other pipeline updates.

This is an excellent update! Let's examine: - On **June 24, 2026**, Viking Therapeutics announced the initiation of a **Phase 1 single ascending dose (SAD)** clinical trial of **VK3019**, an investigational dual amylin and calcitonin receptor agonist (DACRA), which is being developed as a potential subcutaneous treatment option for weight loss. - Preclinical data of VK3019 showed impressive results: up to 8% body weight reduction in rats at 72 hours. - Viking is currently conducting Phase 3 **VANQUISH** studies for subcutaneous VK2735 (dual GLP-1/GIP receptor agonist): **VANQUISH-1** (adults with obesity) and **VANQUISH-2** (adults with obesity and type 2 diabetes). These are 78-week studies. - Viking is also developing an **oral tablet formulation of VK2735**, and plans to initiate a Phase 3 trial to evaluate oral VK2735 later in 2026 (this aligns with our active watch: `Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation`). - Viking is also doing a **Phase 1 maintenance study** of VK2735 (exploring biweekly/monthly SC or daily/weekly oral maintenance regimens), which was initiated in October 2025, and expects to report results in **3Q26** (this aligns with our active watch: `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout`). Let's do a search on Structure Therapeutics (GPCR) and its pipeline, specifically aleniglipron (GSBR-1290) and the upcoming Phase 3 trials in Q3 2026. Let's do a web search.

Let's fetch the SEC filing or press release from May 7, 2026: `https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-first-quarter-2026-financial` or another recent press release to verify the exact status of the Phase 3 initiation for aleniglipron. Let's do a search first on Structure Therapeutics' latest earnings or news from June/July 2026. Let's run a search.

Let's fetch the June 5, 2026 press release: `https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-publication-nature-medicine/` (it is about the publication in Nature Medicine and the ADA 2026 spotlight, which we have a prior finding on: `[[structure-therapeutics-aleniglipron-access-ii-results]]`). Let's fetch it to see what details it has on the Phase 3 design and timeline.

This is great. Let's look closely at: 1. **Structure Therapeutics (GPCR)** has confirmed that its **Phase 3 program for aleniglipron** is on track to initiate in **Q3 2026** (this directly relates to our watch: `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation`). 2. The Phase 3 program will evaluate multiple doses, starting with a **lower starting dose of 2.5 mg** to improve GI tolerability, following feedback from the FDA and the Phase 2b ACCESS trial. 3. The publication in *Nature Medicine* and presentations at ADA 2026 highlighted that patients on aleniglipron continued to lose weight through the open-label extension (OLE) with no apparent plateau, reaching weight loss of 13.3%, 16.2%, and 15.3% in patients from the 45 mg, 90 mg, and 120 mg arms, respectively, at week 56 (median 20 weeks follow-up in OLE after 36 weeks double-blind). 4. Most importantly, Structure also presented preclinical data at ADA 2026 showing that **combination treatment** of oral small molecule GLP-1 receptor agonist **aleniglipron** and oral small molecule amylin receptor agonist **ACCG-2671** demonstrated **additional weight loss** than monotreatment in obese non-human primates (NHPs). This shows Structure is also building a combination strategy (GLP-1 + amylin) to mimic or compete with Lilly and Viking. Let's do a search on Amgen's tax court case and MariTide. Let's see if there are any updates on Amgen's tax court ruling (H2 2026 expected) or MariTide Phase 2 results. First, let's search for "Amgen" "tax court" "2026" or "MariTide" "Phase 2" "2026". Let's run a search.

This is very helpful. Let's analyze the Amgen updates: 1. **Amgen (AMGN)** is currently in Phase 3 development of **MariTide (maridebart cafraglutide)**, a dual GIP receptor antagonist and GLP-1 receptor agonist, with Phase 3 trials initiated and expected to read out in late 2026 or 2027. (Wait, let's look at when MariTide Phase 2 results or Phase 3 trials are scheduled). 2. Regarding the **IRS Tax Court ruling**, Amgen's latest disclosures (e.g. from early 2026 / mid 2026) confirm that the company expects a decision from the U.S. Tax Court **no earlier than the second half of 2026**. This remains a major overhang, but the timeline is consistent with our active watch: `Amgen 2010–2015 IRS Tax Court Ruling`. 3. Let's do a search on MariTide's specific Phase 2 readout or Phase 3 trials in 2026 to see if there are any updates or if there is a more precise date. Let's run a search.

Ah, interesting! Amgen's Phase 2 data for MariTide was presented at the ADA 85th Scientific Sessions in June 2025. It showed up to 20% weight loss. Currently, Amgen has initiated its Phase 3 MariTide studies (which are 72-week studies). Wait, let's search if there are any other recent updates on Amgen's obesity pipeline or if they have any other obesity drug candidates. Let's do a quick search on "Amgen" "obesity" "2026" or "AMG 133" (MariTide is AMG 133). Let's search for "Amgen" "obesity" pipeline or "MariTide" "2026".

Okay, let's look for updates on GLP-1 reimbursement and coverage cuts. This is a crucial element of the brief: "beyond pharma, track how GLP-1 adoption is affecting adjacent sectors... insurers revising coverage policies or cost projections." Let's do a web search on "GLP-1 coverage cuts" "employers" OR "insurers" 2026. Let's see what has changed recently or what the latest trends are. Let's run a search.

Look at this! This is a massive development. Let's fetch the WaPo article: `https://www.washingtonpost.com/health/2026/07/12/cvs-exec-explains-why-your-health-plan-wont-cover-glp-1s-weight-loss/` and the CNBC article: `https://www.cnbc.com/amp/2026/06/26/glp1-weight-loss-drug-pills-insurance-plan-coverage.html`. I'll fetch WaPo first.

Wait, let's fetch the CNBC article `https://www.cnbc.com/amp/2026/06/26/glp1-weight-loss-drug-pills-insurance-plan-coverage.html` as well. Then we can search for more details or other sources if needed. Let's do a web search to check for the full context of the Cigna and Mercer updates, or other news on employer coverage rollbacks. Let's fetch the CNBC article first.

This is an incredibly rich article! Let's analyze what we have here: 1. **Employer coverage rollbacks**: - In 2025, nearly half of all large employers covered GLP-1 medications. But costs have become prohibitive, with 51% of employers citing GLP-1s as the top driver of rising prescription drug costs (NFP survey). - A Mercer study showed that among employers with 500+ employees, **6% dropped GLP-1 coverage in 2026**, and **5% are planning to drop or are actively considering doing so for 2027**. - A Business Group on Health survey found that among companies that cover GLP-1s, **10% are unlikely or very unlikely to continue coverage in 2027** for cost reasons. - Some employers are tightening clinical criteria (e.g., raising the qualifying BMI from 30 to 35, or requiring strict behavior management programs). - Cigna announced on June 2, 2026, that it would **stop covering GLP-1 obesity drugs (like Wegovy and Zepbound) for its own employees** effective July 1, 2026. This is a massive symbolic and practical move by a major health insurer. 2. **Pills vs. Injectables Economics**: - Oral versions of GLP-1s (Wegovy pill launched in Jan 2026, Lilly's Foundayo launched in April 2026) are priced essentially the same as injectables for employers. - However, clinical trials show that pills are slightly less effective for weight loss than injectables (Oasis trial daily 25-mg Wegovy pill showed 17% weight loss, vs higher weight loss from some injectables or newer pipelines), and employers are concerned that the ease of a pill will explode demand while providing no discount. - Some employers may decide *not* to put the oral pills on their formularies at all. 3. **Alternative Access / Cash Pay Models**: - Direct-to-consumer cash prices for oral GLP-1s (Wegovy pill and Foundayo) start at **$149 per month** for the lowest doses (compared to $199 for Wegovy injectable and $299 for Zepbound injectable without insurance). - Eli Lilly launched its **Lilly Employer Connect** platform with over 15 independent program administrators (including 9amHealth, GoodRx, Goodpath) to offer tailored obesity coverage options. - Medicare launched a new initiative under which GLP-1s are available through Medicare for as low as **$50 per month** starting July 1, 2026. Wait, let's update our prior findings on employer coverage cuts. The prior finding slug is `employer-glp1-coverage-cuts-cigna`. We should update this finding to include: - Cigna's June 2, 2026 announcement that it will stop covering GLP-1 weight-loss drugs for its own employees starting July 1, 2026. - The Mercer study results: 6% of large employers (500+ employees) dropped coverage in 2026, and 5% are planning or considering doing so for 2027. - The Business Group on Health survey finding that 10% of employers covering GLP-1s are likely or very unlikely to continue doing so in 2027. - CVS Health CEO's comments on July 12, 2026, explaining that broader insurance coverage will have to wait until prices come down and clear evidence of healthcare cost reduction emerges. - The economics of the oral weight-loss pills (Wegovy pill and Foundayo), which are priced similarly to injectables for employers but are expected to increase demand, leading employers to tighten criteria or exclude them from formularies. Let's do a search on bariatric surgery and medtech. "GLP-1 impact medtech bariatric surgery decline" is our prior finding `glp1-impact-medtech-bariatric-surgery-decline`. Let's search if there are any recent updates on medtech companies (like Intuitive Surgical, Johnson & Johnson, Medtronic) seeing further impacts or adjusting their outlooks in mid-2026. Let's run a search.

Let's check the Intuitive Surgical article: `https://www.massdevice.com/intuitive-says-davinci-systems-exceeded-expectations-it-wants-more/` or do a quick search on "Intuitive Surgical" "bariatric" "2026" to see what the latest numbers or comments are. Let's run a search.

Let's fetch the first article `https://www.massdevice.com/intuitive-says-davinci-systems-exceeded-expectations-it-wants-more/` to see if we can find any comments on bariatric surgery or procedural mix from mid-2026. Wait, let's look at the URL first. Let's fetch it.

This is incredibly valuable! Let's see what we have here: 1. **Intuitive Surgical (ISRG)** CEO Dave Rosa stated at the 2026 J.P. Morgan Healthcare Conference that: - "With the popularity of GLP-1 inhibitors, **bariatric surgery, once a sizable portion of robotic-assisted procedures, has dropped to under 3% of U.S. robotic surgeries**, signaling a shift in patient need, according to Rosa." - "The trend is forcing Intuitive and its competitors to expand their treatment scope and system capabilities." - This is a direct, concrete metric and quote from the CEO of the leading robotic surgery company (Intuitive Surgical) in 2026! It shows exactly how GLP-1 adoption is impacting the medtech sector, specifically bariatric surgery, driving it down to under 3% of U.S. robotic surgeries. - This is perfect for updating the prior finding `glp1-impact-medtech-bariatric-surgery-decline`. Let's organize our findings. We have three main areas to update or write new findings for: 1. **Novo Nordisk's oral Wegovy EU approval and comparative oral market dynamics**: - The European Commission approved Novo Nordisk's oral Wegovy (25mg semaglutide pill) on July 15, 2026. It is the first oral GLP-1 cleared for weight management in the EU. - The EC also approved the high-dose, 7.2-mg version of the Wegovy pen (Step Up trial showed 20.7% weight loss vs 17.5% for 2.4-mg). - Comparative data shows Novo's oral Wegovy pill is dominating Eli Lilly's oral Foundayo (orforglipron) in the US market. Weekly IQVIA data shows Wegovy pill logged **153,000 weekly US prescriptions**, compared with **19,550 for Foundayo** in its 13th week on the market. - This is a perfect update or new finding. Wait, does it fit into `glp1-competitive-landscape-ada-2026` or is it a new finding? Let's check our prior findings. - `glp1-competitive-landscape-ada-2026` is "The GLP-1 Competitive Landscape: Pfizer's Monthly Injectable and Viking's Phase 3 Expansion Reshape the Race for Third". - We can update `glp1-competitive-landscape-ada-2026` or write a new note. Wait, the guidelines say: "Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate... never the transient story-of-the-day... When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place." - Let's check if there is a better slug. `glp1-competitive-landscape-ada-2026` is a bit specific with "ada-2026". But we can reuse it or write a more general slug like `glp1-oral-formulation-market-race`? Wait, let's look at `read_notes` to see all available notes and slugs first! Let's call `read_notes`.

This is a fantastic list of existing notes! Let's see which slugs we have that match our research subjects: 1. **Novo Nordisk's oral Wegovy EU approval**: - We have an existing note with slug `ema-backs-novo-nordisk-oral-wegovy-tablets` ("European and UK Regulatory Milestones for Novo Nordisk's Oral Wegovy Tablets"). - This was updated on June 29, 2026. - The European Commission approved it on July 15, 2026. - This is the perfect slug to update! Let's write the updated note under the slug `ema-backs-novo-nordisk-oral-wegovy-tablets`. 2. **Viking Therapeutics (VKTX) and VK3019/VK2735**: - We have an existing note with slug `viking-therapeutics-oral-vk2735-phase-2-venture` ("Viking Therapeutics Expands Metabolic Pipeline with Novel Amylin Agonist VK3019 and Progresses VANQUISH Phase 3 Trials"). - This was updated on July 13, 2026. - Let's check if there are new details to add. Wait, we have the June 24, 2026 press release on the initiation of the Phase 1 SAD trial for VK3019 (investigational dual amylin and calcitonin receptor agonist / DACRA). Let's review if we need to update it. Yes, we can update it with more specific details or keep it as is if it's already well covered. Let's make sure it's updated with the exact details from the June 24, 2026 press release. Wait, let's first read the body of `viking-therapeutics-oral-vk2735-phase-2-venture` to see if it already includes this, or if we should refine it. Let's fetch the note body or read notes. Wait, `read_notes` only gives the preview. Let's read the note. Wait, is there a tool to read the note body? No, we don't have a direct "read_note_body" tool, but we can call `write_note` to update it, or we can just update it with our new findings. Let's do a quick search on viking in our notes. 3. **Employer coverage cuts**: - We have `employer-glp1-coverage-cuts-cigna` ("Employers Roll Back GLP-1 Coverage for Weight Loss as Exploding Demand and New Oral Options Fuel Cost Concerns"). - This was updated on June 29, 2026. - Now we have the June/July 2026 updates: Cigna's actual implementation on July 1, 2026 (dropping coverage for its own employees), the Mercer study (6% of large employers dropped coverage in 2026, 5% planning/considering for 2027), the Business Group on Health survey (10% unlikely/very unlikely to continue in 2027), and the CVS Health CEO's comments on July 12, 2026. - This is a perfect update for `employer-glp1-coverage-cuts-cigna`. 4. **Bariatric surgery decline**: - We have `glp1-impact-medtech-bariatric-surgery-decline` ("GLP-1 Obesity Drugs Fuel Plunge in Bariatric Surgery Rates, Creating Long-Term Uncertainty for Medtech"). - This was updated on June 29, 2026. - Now we have the July 2026 update: Intuitive Surgical (ISRG) CEO Dave Rosa stating at the 2026 J.P. Morgan Healthcare Conference that bariatric surgery has dropped to **under 3% of U.S. robotic surgeries** (from once being a sizable portion), forcing medtech companies to expand their treatment scope. - This is a perfect update for `glp1-impact-medtech-bariatric-surgery-decline`. Let's check if there are any other notes we should update. How about `structure-therapeutics-aleniglipron-access-ii-results`? - We have the June 5, 2026 press release on the publication in *Nature Medicine* and the ADA 2026 spotlight, which is already the subject of `structure-therapeutics-aleniglipron-access-ii-results`. Let's see if we should refine it or if it's already complete. Since it was updated on June 22, 2026, it likely has the June 5, 2026 data. Let's research the exact details of the European Commission approval of oral Wegovy. Let's fetch the Reuters or Pharmaceutical Technology article to get more details on oral Wegovy and high-dose Wegovy pen. Let's fetch `https://www.pharmaceutical-technology.com/news/novo-secures-european-approval-for-oral-wegovy-to-extend-lead-over-lilly/`.

This is a superb article! Let's examine: 1. **European Commission Approval**: - The EC granted marketing authorization on July 15, 2026 for **oral Wegovy (semaglutide)** for adults with obesity or overweight with at least one weight-related comorbidity. - This follows approvals in the US (January 2026) and UK (June 2026), giving Novo Nordisk a massive first-mover advantage across all three major territories. 2. **Clinical Data**: - The Wegovy pill is taken daily and contains semaglutide. Users lose just under 14% of body weight on average over 64 weeks. - In the **OASIS clinical program**, patients taking the **higher 25mg dose** saw weight loss of around **17%**, with one-third losing at least **20%** of their body weight. 3. **Market Performance and Lead**: - In the US, the Wegovy pill has seen "one of the strongest US pharmaceutical launches by volume on record" since its January 2026 launch. More than **three million prescriptions** of oral Wegovy have been issued in the US alone as of June 2026 (a prescription filled every five seconds over the first five months). - In Europe, Eli Lilly has **not yet filed for regulatory approval of Foundayo (orforglipron)**, and is not expected to launch on the continent until late 2026 or 2027 (or maybe even later, as some sources say 2027). This gives Novo a multi-month, if not multi-year, head start in Europe. 4. **Market Projections**: - According to GlobalData, the obesity market is projected to grow at a CAGR of 32.3% until 2031, reaching sales of **$173.5 billion** across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, UK, US). Let's do a quick check on the exact URL for the market view of Novo Nordisk to cite it: `/markets/NVO/2026/07/20`. And for Eli Lilly: `/markets/LLY/2026/07/20`. Let's write our first note to update `ema-backs-novo-nordisk-oral-wegovy-tablets`. Wait, let's review the title of `ema-backs-novo-nordisk-oral-wegovy-tablets`: "European and UK Regulatory Milestones for Novo Nordisk's Oral Wegovy Tablets". We will update this note with the July 15, 2026 European Commission approval, adding the OASIS clinical trial details (25mg dose showing 17% weight loss, 1/3 of patients losing ≥20%), the European Commission's concurrent approval of the high-dose 7.2-mg Wegovy pen (Step Up trial showing 20.7% weight loss), and the massive commercial gap in the US between Novo's Wegovy pill (3 million prescriptions in the first 5 months, 153,000 weekly prescriptions in July 2026) and Lilly's Foundayo (19,550 weekly prescriptions in its 13th week on the market). This shows Novo's first-mover advantage is widening. Let's write this note now. I will construct the markdown body carefully. No YAML frontmatter. First heading is `# European and UK Regulatory Milestones for Novo Nordisk's Oral Wegovy Tablets`. Let's do it.

This is a great update. Now, let's look at updating `employer-glp1-coverage-cuts-cigna` with the latest employer rollbacks and insurance dynamics. Let's review what we have: - **Cigna's actual implementation**: Cigna formally dropped GLP-1 weight-loss drug coverage (such as Wegovy and Zepbound) for its own employees effective July 1, 2026. This was announced on June 2, 2026. - **Mercer Study (June 2026)**: - 6% of large employers (500+ employees) dropped coverage in 2026. - 5% are planning to drop or are actively considering dropping coverage for 2027. - **Business Group on Health Survey**: - Among companies that cover GLP-1s, 10% are unlikely or very unlikely to continue coverage in 2027 due to prohibitive costs. - 87% of employers expect oral GLP-1 medications to increase demand, while only 9% predict a price drop. - **CVS Health (Aetna) CEO Comments (July 12, 2026)**: - Broader insurance coverage of GLP-1 weight-loss drugs will have to wait until prices come down and clear evidence emerges that they reduce overall healthcare costs. - **Economics of Oral GLP-1s**: - Oral formulations (Wegovy pill and Foundayo) are priced essentially the same as injectables (net prices around $569 to $664 a month per employee after discounts, and list prices from $1,000 to $1,350). - Employers fear that oral formulations will make the drugs even more popular, driving up total costs while offering no discount. - This is leading some employers to exclude oral formulations from their formularies completely or tighten qualifying clinical criteria (e.g., raising BMI requirements from 30 to 35, requiring behavior management, or restricting to type 2 diabetics). - **Alternative Access / Cash Pay Models**: - Direct-to-consumer cash prices for oral GLP-1s start at $149/month for low doses. - Eli Lilly's Lilly Employer Connect platform has partner programs to help employers offer structured direct-to-consumer access. - Medicare GLP-1 Bridge program offers low copays ($50/month) starting July 1, 2026. Let's write this update under slug `employer-glp1-coverage-cuts-cigna`. First heading is `# Employers Roll Back GLP-1 Coverage for Weight Loss as Exploding Demand and New Oral Options Fuel Cost Concerns`. Let's do it.

Excellent. Now let's update `glp1-impact-medtech-bariatric-surgery-decline` with the latest medtech and bariatric surgery data. Let's review what we have: - **Intuitive Surgical (ISRG) CEO Dave Rosa comments at the 2026 J.P. Morgan Healthcare Conference**: - "With the popularity of GLP-1 inhibitors, **bariatric surgery, once a sizable portion of robotic-assisted procedures, has dropped to under 3% of U.S. robotic surgeries**, signaling a shift in patient need, according to Rosa." - This is a massive, highly specific metric that quantifies the exact impact on robotic surgery and bariatrics. - "The trend is forcing Intuitive and its competitors to expand their treatment scope and system capabilities." - To offset this bariatrics headwind, Intuitive is investing heavily in its **Ion robotic bronchoscopy system** (minimally invasive lung biopsy), which saw a **51% increase in procedure use globally in 2025**. - Intuitive's procedure volume overall is expected to grow 13% to 15% in 2026, driven by da Vinci 5 adoption and software advancements, showing that they are successfully diversifying away from bariatrics. - Competitors are also expanding: Medtronic's Hugo system (focused on urology) earned FDA approval in late December 2025, and J&J submitted its Ottava system for FDA de novo approval in early January 2026. Let's write this update under slug `glp1-impact-medtech-bariatric-surgery-decline`. First heading is `# GLP-1 Obesity Drugs Fuel Plunge in Bariatric Surgery Rates, Creating Long-Term Uncertainty for Medtech`. Let's do it.

Ah, the web_search budget is spent. No problem, we have gathered exceptionally high-quality primary evidence and updated three major notes! Let's double-check if we need to record any events or watches. Let's review the listed threads: 1. `Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation` (ID: `019f1276-b10a-78d3-b927-e66538b793ea`): Viking plans to initiate oral VK2735 Phase 3 by the end of 2026. This is still forward-looking, so we don't resolve it yet. 2. `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` (ID: `019f1276-a5e0-7c66-acda-94e3069c4e57`): Lilly plans to launch in late 2026 or early 2027. Still forward-looking. 3. `Amgen 2010–2015 IRS Tax Court Ruling` (ID: `019eee6b-f720-751d-bfad-39abdc23dbf4`): Expected in the second half of 2026 (no earlier than H2 2026). Still forward-looking. 4. `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation` (ID: `019eca60-7750-771f-9690-cf5d740535b4`): Expected to initiate in Q3 2026. Still forward-looking. 5. `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` (ID: `019eca60-6c6d-7660-9cf6-fbcd998a78d9`): Expected in Q3 2026. Still forward-looking. Since all these watches are active and their fire dates are in Q3 2026, late 2026, or early 2027, and we are currently on July 20, 2026, none of them have fired yet. We will leave them open for future cycles to monitor and resolve. Wait, are there any other open threads or did we resolve any existing threads? Let's check the listed threads again. All 5 are of kind `watch` (registered watches). There are no other open threads. Wait! Let's check if we should register any new watches or threads. We have: - Novo Nordisk's oral Wegovy EU approval on July 15, 2026. This was a major dated catalyst that happened! But we didn't have an active watch specifically for the EU approval of oral Wegovy (we had a note `ema-backs-novo-nordisk-oral-wegovy-tablets` and we updated it directly). - Let's check if there are other forward-looking catalysts we should register as a watch. - How about Viking's Phase 1 SAD study of VK3019 (amylin/calcitonin agonist)? It initiated on June 24, 2026. Let's register an ongoing or one-shot watch for its Phase 1 data readout. Since the trial has just initiated in June 2026, a readout could be expected in late 2026 or H1 2027. Let's register a watch for Viking's VK3019 Phase 1 SAD trial data readout. - How about Structure Therapeutics' Phase 3 registrational program for oral aleniglipron (GSBR-1290) in Q3 2026? We already have a watch for that: `Structure Therapeutics Q3 2026 Phase 3 Aleniglipron Trial Initiation`. - Let's register a watch for Viking Therapeutics' VK3019 Phase 1 SAD data readout. Let's do that. Let's call `record_watch` for Viking's VK3019 Phase 1 SAD data readout. Let's set a tentative fire date of June 30, 2027 (H1 2027) as Phase 1 SAD in healthy adults usually takes several months to a year. Let's do it.

Excellent! This is a very clean and professional research cycle. Let's call `finish_cycle` to complete this cycle. I have updated three major notes with high-quality citations and quotes, registered a forward-looking watch, and thoroughly addressed the user's brief. No threads were resolved because all active threads are watches that are still forward-looking. I will now call `finish_cycle`.

I have completed the research cycle for this topic. Here is a summary of the findings and updates recorded in this cycle: ### 1. European Regulatory Milestone for Oral Wegovy * **Finding Updated:** `[[ema-backs-novo-nordisk-oral-wegovy-tablets]]` * **Key Developments:** On **July 15, 2026**, the European Commission formally approved Novo Nordisk’s once-daily **oral Wegovy (semaglutide)** tablet, making it the first and only oral GLP-1 receptor agonist approved for weight management in the EU. * **Clinical Strength:** In the OASIS-1 trial, oral Wegovy (25-mg dose) showed a **17% average weight loss** (vs. 3% for placebo), with one-third of patients losing at least 20% of their body weight. Concurrently, the European Commission approved a high-dose, 7.2-mg version of Novo's injectable Wegovy pen (Step Up trial showed **20.7% average weight loss**). * **Competitive Edge:** This approval grants Novo Nordisk a clean-sweep first-mover advantage over Eli Lilly across the US, UK, and Europe. Lilly has not yet filed for regulatory approval of its oral non-peptide competitor **Foundayo (orforglipron)** in Europe, delaying its European launch until late 2026 or 2027. Weekly US prescription data from July 2026 reveals a massive volume gap: oral Wegovy logged **153,000 weekly US prescriptions**, compared to **19,550 for Foundayo** in its 13th week on the market. ### 2. Escalating Employer Coverage Rollbacks * **Finding Updated:** `[[employer-glp1-coverage-cuts-cigna]]` * **Key Developments:** On **July 1, 2026**, major health insurer **Cigna** officially implemented its decision to completely drop GLP-1 weight-loss drug coverage (such as Wegovy and Zepbound) for its own employee health plan. * **Macro Trends:** A June 2026 Mercer survey of employers with 500+ workers showed that **6% dropped GLP-1 weight-loss coverage in 2026**, with **5% planning or actively considering cuts for 2027**. * **Oral Pill Anxiety:** Despite hopes that oral options would lower costs, they are priced similarly to injectables (with net costs to employers averaging **$569 to $664/month per employee** after PBM discounts). Employers fear that oral pills will explode patient demand, driving up total pharmacy costs. On **July 12, 2026**, CVS Health's CEO stated that broader insurance coverage will remain frozen until prices decline and clear evidence of overall healthcare cost reductions emerges. In response, employers are raising qualifying BMI thresholds (from 30 to 35) or pivoting to structured cash-pay programs like **Lilly Employer Connect** (which offers direct-to-consumer access starting at $149/month for low doses). ### 3. Medtech Re-Anchoring Amid Bariatric Surgery Decline * **Finding Updated:** `[[glp1-impact-medtech-bariatric-surgery-decline]]` * **Key Developments:** At the 2026 J.P. Morgan Healthcare Conference, **Intuitive Surgical** (NASDAQ: ISRG) CEO Dave Rosa provided a definitive metric on the impact of GLP-1s on metabolic surgery: > "With the popularity of GLP-1 inhibitors, bariatric surgery, once a sizable portion of robotic-assisted procedures, has dropped to under 3% of U.S. robotic surgeries, signaling a shift in patient need, according to Rosa." * **Industry Pivot:** To offset this headwind, medtech companies are pivoting aggressively. Intuitive is investing heavily in its **Ion robotic bronchoscopy system** for minimally invasive lung cancer biopsies, which saw a **51% global surge in procedure volume in 2025**. Intuitive is also rolling out its next-generation **da Vinci 5** system (featuring force-feedback haptics). Meanwhile, Medtronic's Hugo surgical robot (focused on urology) secured FDA approval in late December 2025, and J&J submitted its Ottava robotic system for FDA de novo approval in early January 2026. Despite the bariatric decline, Intuitive expects overall da Vinci procedure volumes to grow **13% to 15% in 2026**, demonstrating that the broader robotic surgery market is successfully diversifying. ### 4. Forward-Looking Monitoring (New Watch Registered) * **Viking Therapeutics (VKTX):** Registered a new watch tracking the top-line results of Viking’s **VK3019 Phase 1 single ascending dose (SAD) trial** (initiated on June 24, 2026). VK3019 is a dual amylin and calcitonin receptor agonist (DACRA) being developed as a potential subcutaneous treatment option for weight loss. If successful, it would validate Viking's second metabolic weight-loss mechanism alongside its dual GLP-1/GIP agonist VK2735.